Months after an initial ₹90 Cr raise, Bengaluru-based 4baseCare has closed its Series B round at ₹128 Cr by securing an additional ₹38 Cr led by growX Ventures. The funding will accelerate its genomics laboratory expansion and AI oncology platform scaling across India and multiple international regions.
- Series B round now totals ₹128 Cr ($13M) with new ₹38 Cr infusion
- Funds to expand genomics labs globally and scale AI oncology platform
- Part of broader surge in Indian healthtech funding driven by AI
What happened
4baseCare, a Bengaluru healthtech startup specializing in genomics-driven oncology solutions, announced the closing of its Series B funding round at ₹128 crore (approximately $13 million). This milestone follows a previous ₹90 crore raise earlier in the round, with the recent ₹38 crore investment led by growX Ventures and contributions from existing investors. The company intends to use these funds to broaden its genomics laboratory network beyond India into the Middle East, Southeast Asia, Latin America, and Central Asia.
Additionally, a significant portion of the new capital will be allocated to scaling OncoTwin, 4baseCare’s AI-powered precision oncology platform, which delivers actionable insights to clinicians by integrating genomic, clinical, environmental, and lifestyle data. Founded in 2018, 4baseCare combines advanced biotech and AI technologies to offer personalized cancer treatment solutions.
Why it matters
This funding round highlights increased investor confidence in Indian healthtech startups, particularly those leveraging AI and genomics to transform patient care. With cancer being a leading health challenge, 4baseCare’s approach to personalized oncology driven by data science and AI represents a significant advancement in precision medicine. The company’s focus on building a comprehensive genomic and clinical database underscores the potential to improve treatment outcomes and tailor therapies more effectively.
Moreover, the global expansion plans indicate an ambition to address cancer care disparities across emerging markets. This aligns with wider trends in India’s healthtech ecosystem, where startups are shifting attention from episodic treatment models to continuous monitoring, prevention, and longevity, boosting the overall healthcare innovation landscape.
What to watch next
Monitor how 4baseCare executes its international expansion and whether it can successfully establish a presence in diverse healthcare markets across Asia, Latin America, and Central Asia. The effectiveness and adoption rate of OncoTwin’s AI-driven insights by medical professionals will also be critical to watch, as these will determine the platform’s impact on cancer treatment personalization.
In a broader context, 4baseCare’s progress will be indicative of the momentum in India's healthtech funding environment, especially the role AI plays in advancing longevity and precision medicine solutions. The company’s trajectory could encourage further investment and innovation across this burgeoning sector.